EC Number | Application | Comment | Organism |
---|---|---|---|
2.3.2.3 | medicine | MprF could be a target for new anti-virulence drugs | Staphylococcus aureus |
EC Number | Cloned (Comment) | Organism |
---|---|---|
2.3.2.3 | into the vector pET28 | Staphylococcus aureus |
EC Number | Protein Variants | Comment | Organism |
---|---|---|---|
2.3.2.3 | D546A | MprF(-8) mutant, replacement results in slightly reduced production of lysyl-phosphatidylglycerol, same result is obtained when the mutation is introduced into the full-length MprF protein | Staphylococcus aureus |
2.3.2.3 | D731A | MprF(-8) mutant, exchange leads to complete abrogation of lysyl-phosphatidylglycerol production, same result is obtained when the mutation is introduced into the full-length MprF protein | Staphylococcus aureus |
2.3.2.3 | E624A | MprF(-8) mutant, exchange leads to complete abrogation of lysyl-phosphatidylglycerol production, same result is obtained when the mutation is introduced into the full-length MprF protein | Staphylococcus aureus |
2.3.2.3 | E685A | MprF(-8) mutant, replacement results in strongly reduced production of lysyl-phosphatidylglycerol, same result is obtained when the mutation is introduced into the full-length MprF protein | Staphylococcus aureus |
2.3.2.3 | K547A | MprF(-8) mutant, exchange leads to complete abrogation of lysyl-phosphatidylglycerol production, same result is obtained when the mutation is introduced into the full-length MprF protein | Staphylococcus aureus |
2.3.2.3 | K621A | MprF(-8) mutant, exchange leads to complete abrogation of lysyl-phosphatidylglycerol production, same result is obtained when the mutation is introduced into the full-length MprF protein | Staphylococcus aureus |
2.3.2.3 | K806A | MprF(-8) mutant, exchange leads to complete abrogation of lysyl-phosphatidylglycerol production, same result is obtained when the mutation is introduced into the full-length MprF protein | Staphylococcus aureus |
2.3.2.3 | MprF(-10) | mutant, truncated protein consisting of residues 363-840 | Staphylococcus aureus |
2.3.2.3 | MprF(-12) | mutant, truncated protein consisting of residues 437-840 | Staphylococcus aureus |
2.3.2.3 | MprF(-14) | mutant, truncated protein consisting of residues 510-840 | Staphylococcus aureus |
2.3.2.3 | MprF(-2) | mutant, truncated protein consisting of residues 84-840 | Staphylococcus aureus |
2.3.2.3 | MprF(-4) | mutant, truncated protein consisting of residues 157-840 | Staphylococcus aureus |
2.3.2.3 | MprF(-6) | mutant, truncated protein consisting of residues 219-840 | Staphylococcus aureus |
2.3.2.3 | MprF(-8) | mutant, truncated protein consisting of residues 274-840 | Staphylococcus aureus |
2.3.2.3 | MprF(-C) | mutant, truncated protein consisting of residues 1-586 | Staphylococcus aureus |
2.3.2.3 | R734A | MprF(-8) mutant, exchange leads to complete abrogation of lysyl-phosphatidylglycerol production, same result is obtained when the mutation is introduced into the full-length MprF protein | Staphylococcus aureus |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
2.3.2.3 | membrane | - |
Staphylococcus aureus | 16020 | - |
EC Number | Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|---|
2.3.2.3 | 39000 | - |
theoretical, MprF(-14) mutant, truncated protein consisting of residues 510-840 | Staphylococcus aureus |
2.3.2.3 | 48000 | - |
theoretical, MprF(-12) mutant, truncated protein consisting of residues 437-840 | Staphylococcus aureus |
2.3.2.3 | 56000 | - |
theoretical, MprF(-10) mutant, truncated protein consisting of residues 363-840 | Staphylococcus aureus |
2.3.2.3 | 67000 | - |
theoretical, MprF(-8) mutant, truncated protein consisting of residues 274-840 | Staphylococcus aureus |
2.3.2.3 | 67000 | - |
theoretical, MprF(-C) mutant, truncated protein consisting of residues 1-586 | Staphylococcus aureus |
2.3.2.3 | 75000 | - |
theoretical, MprF(-6) mutant, truncated protein consisting of residues 219-840 | Staphylococcus aureus |
2.3.2.3 | 80000 | - |
theoretical, MprF(-4) mutant, truncated protein consisting of residues 157-840 | Staphylococcus aureus |
2.3.2.3 | 88000 | - |
theoretical, MprF(-2) mutant, truncated protein consisting of residues 84-840 | Staphylococcus aureus |
2.3.2.3 | 97000 | - |
theoretical, MprF wild-type | Staphylococcus aureus |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.3.2.3 | L-lysyl-tRNALys + phosphatidylglycerol | Staphylococcus aureus | - |
tRNALys + 3-phosphatidyl-1'-(3'-O-L-lysyl)glycerol | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.3.2.3 | Staphylococcus aureus | Q2G2M2 | - |
- |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.3.2.3 | L-lysyl-tRNALys + phosphatidylglycerol | - |
Staphylococcus aureus | tRNALys + 3-phosphatidyl-1'-(3'-O-L-lysyl)glycerol | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.3.2.3 | lysyltransferase | - |
Staphylococcus aureus |
2.3.2.3 | MprF protein | - |
Staphylococcus aureus |
2.3.2.3 | multiple peptide resistance factor protein | - |
Staphylococcus aureus |